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Abstract
To date, the Centre d’Etude Polymorphism Humain (CEPH) cell line model has only been used as a pharmacogenomic tool
to evaluate which genes are responsible for the disparity in response to a single drug. The purpose of this study was
demonstrate the model’s ability to establish a specific pattern of quantitative trait loci (QTL) related to a shared mechanism
for multiple structurally related drugs, the camptothecins, which are Topoisomerase 1 inhibitors. A simultaneous screen of
six camptothecin analogues for in vitro sensitivity in the CEPH cell lines resulted in cytotoxicity profiles and orders of
potency which were in agreement with the literature. For all camptothecins studied, heritability estimates for cytotoxic
response averaged 23.162.6%. Nonparametric linkage analysis was used to identify a relationship between genetic markers
and response to the camptothecins. Ten QTLs on chromosomes 1, 3, 5, 6, 11, 12, 16 and 20 were identified as shared by all
six camptothecin analogues. In a separate validation experiment, nine of the ten QTLs were replicated at the significant and
suggestive levels using three additional camptothecin analogues. To further refine this list of QTLs, another validation study
was undertaken and seven of the nine QTLs were independently replicated for all nine camptothecin analogues. This is the
first study using the CEPH cell lines that demonstrates that a specific pattern of QTLs could be established for a class of
drugs which share a mechanism of action. Moreover, it is the first study to report replication of linkage results for drug-
induced cytotoxicity using this model. The QTLs, which have been identified as shared by all camptothecins and replicated
across multiple datasets, are of considerable interest; they harbor genes related to the shared mechanism of action for the
camptothecins, which are responsible for variation in response.
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Introduction
Prior to the 1990s, the phenotypic-based drug discovery
approach dominated the pharmaceutical industry. In this
approach, small molecules were screened against cells, tissues, or
even whole organisms for their ability to enhance or suppress a
specific phenotype desired in humans. The apparent advantages of
this method over the existing target-based drug discovery
paradigm have resulted in a renewed interest in phenotypic
screening. One of the greatest advantages of this approach is that it
enables the discovery of novel therapeutic targets for a disease.
Drugs are screened for a biological effect rather than perturbation
of a single molecular target, linking chemistry with biology and
driving the serendipitous discovery of numerous structures with
novel mechanisms of action (MOA).
Despite the recent revival in phenotypic screening, there are
noteworthy limitations which can create a considerable bottleneck
in the drug discovery process. Mechanism elucidation following
the identification of hits remains the most important weakness. A
number of methods are being developed and optimized for
mechanism elucidation; however, they are fraught with limitations
which have been reviewed extensively elsewhere [1]. Since the
typical phenotypic screening methods are unable to suggest key
information about the mechanism of biologically active drugs,
there is no way to distinguish between them other than by potency.
Without a clear understanding of MOA, problems arise in lead
optimization, drug safety, and efficacy. Structure activity relation-
ship (SAR) studies for lead optimization become quite complicated
with phenotypic screens. Binding to an unknown target can be
influenced by cell absorption and transport, additional protein
binding, secondary target interactions, drug metabolism, etc.
These sites of drug loss can vary significantly within a series of
structurally related drugs. Most current methods of mechanism
elucidation are also unable to account for or convey changes in
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mechanism (ie primary and secondary targets) with changes in
structure. As a result SAR patterns become difficult to interpret
and use during lead optimization. Finally, when mechanism is
unclear our ability to assess the risk of mechanism based toxicity,
side effects associated with secondary targets, or lapses in efficacy is
also quite limited.
Genetic and genomic methods which screen all possible targets
of drugs of interest are being developed to surmount issues
associated with target identification following phenotypic screens.
These methods which simultaneously screen drugs for a desired
biological effect and provide information about molecular targets
and SAR patterns are rising as powerful tools in drug discovery
and development. Some of the most prominent examples of this
approach use the budding yeast Saccharomyces cerevisiae [2,3] or
human cancer cell lines [4,5] as in vitro model systems. In both
cases, inconsistencies in data between humans and the model are a
significant drawback. An ideal genomic strategy would investigate
drug activity in a normal healthy human model. Recently, an ex
vivo familial genetic strategy involving lymphoblastoid cell lines
(LCLs) derived from Centre d’Etude du Polymorphisme Humain
(CEPH) reference pedigrees was employed to quantify the impact
of genetics on drug response and to identify quantitative trait loci
(QTLs) harboring genes critical to drug action [6,7]. Here we
asked whether this ex vivo familial genetics model could be used to
establish specific patterns of QTLs related to a shared mechanism
for a class of structurally related drugs.
The camptothecins were chosen as a model class of drugs to
investigate for a number of reasons. Extensive efforts in medicinal
chemistry have led to the generation of a large number of
camptothecin derivatives. Two of these, topotecan and irinotecan,
are being used in the clinic as antitumor agents, and many are in
preclinical and clinical development. In spite of the identification
of a number of analogs with improved therapeutic activity,
(intrinsic and acquired) resistance and toxicity remain major
limitations to camptothecin therapy. While extensively studied, the
mechanisms of resistance and toxicity remain unclear [8]. In
addition, though it is firmly established that the key molecular
target of all of the camptothecins is Topoisomerase 1 (Top1), the
post target interaction events responsible for antitumor activity are
vague [9]. It is reasonable to suggest that a clearer understanding
of the biochemical cascade associated with camptothecin cytotox-
icity might lend answers to the questions surrounding mechanisms
of activity, toxicity, and resistance. To this end, the CEPH model
system was used to a) assess variation in response to the
camptothecins across normal healthy human LCLs, b) evaluate
the genetic contribution to variation in response and c) establish a
pattern of multiple QTLs common to a class of drugs suggesting a
shared mechanism of action.
Results
Variation in Camptothecin-Induced Cytotoxicity
Sensitivity to the camptothecins was assessed in 125 lympho-
blastoid cell lines derived from 14 CEPH pedigrees. Cells were
exposed to increasing concentrations of each camptothecin (9
concentrations per drug) for 96 h and growth inhibition relative to
vehicle control was determined. Variation in response to each
camptothecin within and between the CEPH pedigrees was
observed (Figure 1, Supplementary Figure S1). For example, 9AC,
which had the widest range of IC50s, concentration required to
inhibit growth by 50%, had a population mean IC50 of 93 nM
and the IC50 ranged from 7 nM to 4 uM. Boxplots illustrating
variation in cytotoxic response across the entire CEPH population
for each drug are supplied in Dataset S3. Boxplots illustrating
intra- and inter-family variability in response are provided in
Dataset S4. Both the order of potency and IC50s in the CEPH cell
lines are consistent with literature values in cancer cell lines such as
the NCI60 cell line panel (NCI Developmental Therapeutics
Human Tumor Cell Line Screening data, http://dtp.nci.nih.gov/
dtpstandard/InvivoSummary/index.jsp [10].
The data was also used to identify individuals and/or families
which were hypersensitive or resistant to the camptothecins.
Further genetic and genomic studies with these individuals might
lend insight into mechanisms of activity and resistance. A
hierarchal clustering analysis of z-score transformed logIC50
values (where IC50 is the concentration required to inhibit
viability by 50%) was performed keeping family structure intact or
clustering on both drugs and family (Figure S2). The clusters
matched the overall potency (SN38,CPT,9NC,TPT,9AC
,CPT11) in the cell lines studied. CPT11 is most divergent from
the other camptothecins studied (Figure S2). Since CPT11 is the
prodrug of SN38 and requires submicromolar concentrations for
effective cell kill, IC50s across the panel of CEPH cell lines are
considerably higher for CPT11 than other camptothecins
investigated. Of note, there are individuals who are sensitive to
some but not all camptothecins and whole families which are
resistant or sensitive to all camptothecins. For example, pedigree
1408 appears resistant to all camptothecins with the exception of
9AC. All but two members of pedigree 1362 are sensitive to all
camptothecins; two offspring (11982 and 11983) are resistant to all
camptothecins.
Heritability Analysis
Heritability was estimated to quantify the impact of genetic
factors on the cytotoxic response to each of the camptothecins at
each concentration. There is a known correlation between cellular
sensitivity to many chemotherapeutic agents and growth rate
[11,12]. As a control, heritability was calculated for growth rate in
the presence of vehicle. The heritability estimate for growth rate
was low (1.60%) which suggests that environmental factors play a
much larger role than genetics in growth rate. For each
camptothecin, the growth-rate adjusted heritability estimates at
each concentration are featured in Figures 1 and S1. Heritability
Figure 1. Representative dose–response curve for camptothe-
cin analogues. Data points represent the overall population mean
(n = 126) for growth inhibition relative to untreated controls at each
concentration of topotecan. Vertical bars represent the standard
deviation for cell viability across the population. Numbers are the
growth-rate adjusted heritability estimates for each concentration. IC50
represents overall population IC50.
doi:10.1371/journal.pone.0017561.g001
QTLs Linked to Variable Response to Camptothecins
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estimates at the asymptotes of the sigmoidal dose-response curve
are low as there is little to no variability in cytotoxic response at
these points. For all camptothecins studied heritability estimates
averaged 23.162.6% for concentrations within the linear portion
of the sigmoid curve. Since heritability estimates were approxi-
mately 20% for all camptothecins this reinforces the idea that
inherited genetic variation is an important determinant of the
cytotoxic response to camptothecins. The heritability associated
with the cytotoxicity of these drugs is analogous to heritabilities
reported for other common human phenotypes such as systolic
and diastolic blood pressures [13], and for the cytotoxic response
to daunorubicin in CEPH cell lines [14].
Genome-Wide Linkage Analysis
Nonparametric linkage analysis was performed using mean
growth inhibition (relative to a vehicle control) at each
concentration for each camptothecin, which is referred to as the
drug-dose phenotype. A complete set of QTL maps for each
camptothecin, by chromosome can be found in Dataset S5. For
each drug-dose phenotype statistically significant logarithm of
odds (LOD) score thresholds corresponding to a p-values less than
or equal to 0.05 were determined using gene-dropping permuta-
tions under the null hypothesis that no linkage exists. Regions of
the genome referred to as quantitative trait loci (QTLs) were
considered significant if the highest LOD score in the region was
greater than or equal to the predetermined LOD score cut-offs for
each drug-dose combination on a given chromosome. The mean
LOD score cut-off across all phenotypes and chromosomes
indicating significant linkage was 1.37 (range: 0.83–1.72).
Additionally, cutoffs for suggestive linkage were determined for
each drug-dose combination for an alpha of 0.05 for each
chromosome. A region identified as significant in one drug-dose
phenotype was considered replicated in another drug-dose
phenotype if the maximum LOD score in that region surpassed
the significant or suggestive LOD score threshold. The mean LOD
score cut-off across all phenotypes and chromosomes indicating
suggestive linkage was 0.59 (range: 0.41–0.72).
To establish a pattern of QTLs significant to a class of drugs,
regions of the genome which were overrepresented across the
camptothecins were examined. Ten linkage peaks were initially
identified as significant in a given drug-dose combination and
replicated in all of the camptothecins at a number of concentra-
tions (Table 1, Dataset S2). This implies that the same linkage
regions influence the cytotoxic response to all camptothecins over
a broad range of concentrations. The highest LOD score with
genomic significance (2.13) was observed with the 8.0 nM SN38
phenotype and was located on chromosome 20 between 42 and
101 cM (20p12.1–20q13.32), and presumably associated with
Top1 (56 cM, 20q12–q13.1), the primary target of the campto-
thecins. All camptothecin analogues studied (at multiple concen-
tration for each drug) had a peak at chromosome 20 centered
around 50 cM (Figure 2, Dataset S2). Unlike the other significant
linkage peaks, the QTL on chromosome 6 from 0 to 29 cM is only
associated with higher concentrations of the camptothecins which
result in greater than 80% growth inhibition. Figure 3 illustrates
significant and suggestive QTLs identified in one camptothecin
which were replicated in other camptothecins. The results of a sign
test (p,0.5) indicated there was a significant overrepresentation of
overlapping QTLs compared to the null hypothesis that QTLs
were randomly distributed across the genome amongst all drugs.
Moreover, notable distinctions between significant QTLs
associated with camptothecin analogues have been observed and
are summarized in Figure 3. For example, TPT is the only
camptothecin with a linkage peak extending from 0 to 19.6 cM on
chromosome 13 (LOD = 1.365) (Table S3). Interestingly, 9NC is
considered to be the prodrug of 9AC and there is one linkage peak
which was identified exclusively in these drugs on chromosome 5
[15] (Table S3). Chromosome 1 has two QTLs centered at 70 and
129 cM respectively which are shared exclusively by camptothe-
cins possessing a nitrogen bearing substituent on carbon 9: 9AC,
9NC, and TPT (Table S3). No peaks were identified which were
unique solely to SN38 and its prodrug CPT11. However, a QTL
on chromosome 4 is only present in CPT11 and 9AC. Regions
suggested to influence the cytotoxic response to CPT11 were not
always replicated in SN38 or vice versa. This was also observed for
9AC and 9NC. This is unsurprising since for example, the prodrug
CPT11 must undergo activation by carboxylesterases (CESs) to
the active SN38 and SN38 is not subsequently metabolized by
CES. Only suggestive QTLs for CPT11 where located on
chromosome 16 from 1–69 cM; CES1 and CES2 are centered
around 73 cM on chromosome 16. Finally, to compare the overall
QTL patterns a similarity matrix was constructed using a binary
assessment of peaks present at either the significant or suggestive
level for each camptothecin (summary list of peaks used for
similarity matrix in Dataset S2). R squared correlations (r2) are
bound by 0 and 1 and the greater the value the more related the
pattern are to each other (Table S1). The majority of the
correlations are above 0.5, indicating a strong association between
overall QTL patterns for the camptothecins and suggests similar
mechanisms of action. The highest correlations (highest degree of
similarity) are between the 9AC and 9NC, CPT11 and CPT, and
CPT11 and SN38. While the biological profile of CPT11 appears
different from the remaining camptothecins, the genomic profile of
TPT appears most distinct.
Independent Validation of Shared QTLs
Ten QTLs were identified as shared across multiple drug-dose
combinations of six camptothecin analogues (Camptothecin
Group A: 9AC, 9NC, CPT, CPT11, SN38, and TPT). We next
asked whether QTLs identified as shared among all camptothecins
in Group A could be replicated independently in a set of 3
additional but distinct camptothecin analogues (Camptothecin
Group B: mCPT, hCPT, ClCPT). In a separate validation
experiment, the same 14 CEPH pedigrees were exposed to a
dosing spectrum of Group B. Variation in sensitivity to this set of
Table 1. QTLs shared by camptothecin analogues.
Chr Peak Start (cM) Peak End (cM) LODb
1a 229 252 1.855
3d 48 78 1.682
3d 148 180 1.638
5 125 194 1.709
6 0 29 1.528
6 42 65 1.652
11 115 131 1.352
12c 0 6 1.705
16 0 75 1.345
20 42 101 2.134
aBolded QTLs were shared across all three validation sets.
bMaximum LOD score observed in this region.
cQTLs which were not replicated in Camptothecin Group B.
dQTLs which were not replicated in Camptothecin Group A/B.
doi:10.1371/journal.pone.0017561.t001
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camptothecins was then used to calculate heritability estimates at
each drug-dose phenotype. Just as with Group A, heritability
estimates were highest for doses in the linear portion of the
sigmoid curve. Growth rate adjusted heritability estimates for
mCPT, hCPT, and ClCPT at these doses were comparable to
estimates for the analogues belonging to Camptothecin Group A.
The highest heritability estimates for mCPT, hCPT, and ClCPT
were 20.2%, 18.7%, and 20.7% respectively. Linkage analysis,
peak prioritization, and peak replication assessment were repeated
with this second set of camptothecins. Nine of the ten QTLs
identified as characteristic of camptothecin activity in Group A
were subsequently validated in multiple doses of mCPT, hCPT,
and ClCPT (Figure 3, Table 1). While no concentrations of mCPT
or hCPT possessed the shared QTL on chromosome 6 from 0–
29 cM, seven of the eleven doses of ClCPT possessed this shared
QTL. Variation in response across the broad dosing spectrum for
mCPT, hCPT, and ClCPT was not linked to the QTL on
chromosome 12 from 0–6 cM.
This list of QTLs shared by the camptothecins was further
refined by performing a third validation study with seven of the
nine drugs from our initial study (Camptothecin Group A/B:
mCPT, hCPT, 9AC, 9NC, SN38, CPT, TPT). Since Group A/B
was evaluated using the same concentrations and in the same
panel of CEPH cell lines, we consider this a technical replicate of
our previously studies. Any QTLs which could not be replicated at
the significant or suggestive level for all camptothecins within this
separate validation step were excluded from further analysis.
Seven of the nine QTLs were replicated at the significant and
suggestive level for Group A/B (Table 1, Figure 3). The peak on
chromosome 16 was identified as significant in multiple concen-
trations of CPT just as previously reported. In fact, this QTL was
replicated at the significance level in all camptothecins (for n$1
concentrations) from Group A/B. The QTL on chromosome 11
was only present in two concentrations of CPT11 when studying
Group A. In this replication step, it was present in all
camptothecins at the significance level. Multiple concentrations
of both SN38 and CPT11 (Group A) had QTLs on chromosome
20 which surpassed the significance LOD score thresholds in our
earlier work. The QTL on chromosome 20 was replicated at the
significance level in multiple doses of SN38 and at the suggestive
level of all other camptothecin analogues in the Group A/B.
CPT11 was not included in Camptothecin Group A/B. The QTL
on chromosome 5, which was significant in multiple concentra-
tions of analogues from Groups A and B, was also replicated at the
significance level for multiple drug-dose combinations of Group
A/B.
Comparison to Topoisomerase 2 Inhibitors
To illustrate class specific patterns could be established, the
same cell lines were phenotyped for sensitivity to the Topoisom-
erase 2 (Top2) inhibitors, etoposide and teniposide. Genetics plays
a greater role in cytotoxic response to the Top2 inhibitors
compared to Top1 inhibitors. The maximum heritability estimates
for a Top1 inhibitor (topotecan, TPT) was 25.9%, compared to
42.4 and 32.9% for etoposide and teniposide respectively. IC50s
were used to visualize patterns of sensitivity and resistance when
comparing cytotoxic response to the camptothecins across the
entire CEPH cell lines population. We chose another mode of
comparison between the Top1 and Top2 inhibitors since IC50s
could not be obtained for more than 80% of the cell lines treated
with teniposide. Hierarchal clustering using the dose which yields
a population mean growth inhibition of 50% for each drug reveals
that overall patterns of sensitivity and resistance between the Top1
and Top2 inhibitors are indeed distinct and form two clusters
Figure 2. QTL shared across all camptothecins on chromosome 20. The QTL on chromosome 20 contains the gene for Top1, the sole
molecular target of all camptothecins. Each drug is represented by a different color. Multiple concentrations for each drug were identified as
significant and suggestive at this location. The drug-dose combinations with the highest LOD scores are represented here.
doi:10.1371/journal.pone.0017561.g002
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corresponding to differences in mechanism (Figure S3). The same
is true for the dose which yields a population mean growth
inhibition of 40 and 60%.
Linkage analysis was performed using cell viability at each drug-
dose combination of the Top2 inhibitors. Four QTLs present on
chromosomes 6, 12, 13, and 18 were identified as significant and
replicated (considered replicated if LOD.suggestive threshold) in
both Top2 inhibitors at multiple dosages. This pattern of QTLs
for the Top2 inhibitors was quite distinct from those established
for the camptothecins (Figure 3). Unlike the camptothecins, no
QTLs located on chromosome 17 and 3 (chromosomes that carry
topoisomerase II alpha and beta genes, the targets of these
inhibitors) were found. This may not be surprising. An earlier
linkage analysis study of 5-fluoruracil toxicity in CEPH cell lines
failed to identify a significant linkage peak on chromosome 18
around thymidylate synthetase (TYMS), the presumed primary
target of 5FU [6]. In a subsequent association study using the same
LCL samples and HAPMAP SNP data rather than the
microsatellite data used for linkage analysis, SNPs variants
encompassing the TYMS gene were subsequently identified as
significantly associated with 5FU cytotoxicity in the CEPH cell
lines [7]. The genotype density improved when going from the
microsatellite markers used in the preliminary linkage analysis
study of 5FU to the SNP data available for HAPMAP cell lines;
the HAPMAP SNP genotype data enabled the detection of an
association between 5-FU cytotoxicity and TYMS.
Discussion
Early models for chemogenomic studies have used cancer cell
lines [4,5], mutant yeast strains [2,3], and rodents [16,17]. The
biggest limitation with these systems is that the data does not
Figure 3. Genome wide pattern of QTLs for the camptothecins. A. Group A contains camptothecin analogues used in primary screen.
Camptothecin analogues in Group B were used in the validation screen. Camptothecins in Group A/B were rerun from the primary and secondary
screens. Each chromosome was partitioned into 10 cM regions. B. Each drug-dose combination that resulted in a significant QTL (LOD.threshold
value) is indicated in blue. Intensity of the shading indicates the number of doses replicating that QTL at either the suggestive or significant level.
Regions which also had a suggestive QTL (LOD.suggestive threshold) are indicated in green with color intensity referring to the number of doses
replicating this peak.
doi:10.1371/journal.pone.0017561.g003
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always correlate to humans. For example, some mammalian
targets are absent in yeast and vice versa. Targets which produce a
desired phenotype in rodents may not exhibit the same phenotype
in man [18]. In addition, cancer cell lines can differ morpholog-
ically and genetically from primary tissues [19].
This is one of the first genomic studies to use a healthy human
cell line model to identify class specific pharmacological and
genomic profiles. While cancer cell line panels such as the NCI60
are prepared from 4–5 cell lines of a given tissue origin, this study
use a large collection of cell lines of the same type. Just as genetic
heterogeneity across the cancer cell lines has been used to stratify
drugs by mechanistic class, natural genetic variation in the CEPH
cell lines can be used to identify a class specific profile for the
camptothecins [4,20]. In fact, heritability analysis demonstrates
that 23.162.6% of human variation in sensitivity to the
camptothecins is due to genetic components. Not only were these
heritability estimates consistent across multiple concentrations, but
they were consistent across multiple camptothecins analogues and
experiments. Moreover, linkage results for camptothecin-induced
cytotoxicity were replicated across multiple datasets. This finding
reflects the advantage of performing linkage analysis using the
CEPH cell lines over human subjects; cell lines can be grown &
treated under identical conditions and experiments can be
repeated multiple times with the same individuals. This is the
first study to report replication of linkage results for drug-induced
cytotoxicity using the CEPH cell lines.
Using this system to investigate drugs within a structural class
and sharing the same mechanism one would expect a pattern of
QTLs related to the cytotoxic activity of all drugs within that class.
Furthermore, one would expect this pattern of QTLs to be
reproducible across multiple CEPH phenotyping experiments.
Indeed, ten QTLs across seven chromosomes were replicated in
the first six camptothecin analogues studied suggesting a pattern of
QTLs associated with a general and shared mechanism of action.
We consider the fact that these QTLs were replicated across
multiple analogues and doses within the first screen a form of
internal validation. In a separate phenotyping experiment using
three additional camptothecins, nine of those ten QTLs were
again independently replicated. This list was further refined to
seven QTLs which were replicated across multiple drug-dose
combinations in a total three different screens. Finally, both the
biological and genomic profiles generated in CEPH for the
camptothecins and the Topoisomerase 2 inhibitiors, etoposide and
teniposide were very distinct. Hierarchal clustering on biological
data generated two clusters in agreement with the two distinct
mechanisms of action. Moreover, the overall pattern of shared
QTLs differed significantly between the two groups; no QTLs
were present on the same chromosomes for the two classes.
Figure 3 highlights regions which might contain genes that
contribute to the cytotoxic activity of all of the camptothecins.
There are thousands of candidate genes for follow-up under the
QTLs shared by all nine camptothecin analogues alone.
Identifying which of these genes are critical to camptothecin-
induced cytotoxicity can be a challenging and time-consuming
process. To maximize success, a tiered approach is recommended
when choosing QTLs for further investigation. QTLs shared by all
nine camptothecins are considered the most promising (Table 1).
QTLs shared by the first set of six camptothecins should be
investigated next, followed by the QTLs identified as significant
and shared by all three camptothecins in the validation set. Those
significant QTLs which have been identified as unique to 1 or
more drugs but are not replicated even at the suggestive level in all
camptothecins should be considered next. Examples of this class
include the QTLs on chromosome 1 at 70 and 129 cM, and the
linkage peak on chromosome 13 (0–19 cM) that is observed solely
with the 10 nM TPT phenotype. Finally, since the average LOD
score threshold for a suggestive QTL is 0.59, suggestive QTLs
present in all 9 camptothecins at multiple doses should be pursued
last.
Using these prioritization criteria, of the QTLs identified in this
study, the region on chromosome 20 is considered the most
important for follow-up investigations. We used the functional
annotation clustering tool from the web-accessible program
Database for Annotation, Visualization, and Integrated Discovery
(DAVID) to identify over-represented gene ontology terms (GO)
and KEGG pathways for genes under each of the shared QTLs,
including chromosome 20 [21,22] (Table S2). The presence of
Top1, the sole molecular target of all camptothecins, in this region
is encouraging. Top1 expression levels have previously been
correlated with cellular sensitivity to camptothecins; low levels of
Top1 confer resistance to cancer cell lines such as lymphomas [9].
Smirnov et al. performed microarray experiments to measure
human gene expression levels in CEPH [23] (data accessible at
NCBI GEO database [24], accession GSE12626). Baseline
measures of Top1 gene expression varied as much as 2 fold in
this dataset. (Limited overlap between cell lines used in the studies
prevented direct association analysis in the current study.)
Admittedly, since linkage analysis produced a broad QTL
spanning hundreds of genes, it cannot be assumed that a single
gene under this QTL is influencing the activity of these drugs. Bcl-
xl, is another promising gene within this region. Down-regulation
of Bcl-xl, which inhibits apoptosis, has been shown to enhance
cytotoxic response to the camptothecins [25,26]. Association
studies could be used to fine map this and other QTLs and
pinpoint genes associated with drug response; however, limited
statistical power prevents us from doing so here.
Observing significant or suggestive LOD scores for a given drug
across a number of doses has been previously reported as
replication and suggestive of a shared genetic component
contributing to the cytotoxic effect at all concentrations [6,14].
The same regions of interest were not identified as significant or
suggestive for all drug-dose combinations of the camptothecins. In
fact, some QTLs were apparent only in the higher concentrations
of the camptothecins. For example, the QTL on chromosome 6
from 0 to 29 cM is only associated which is shared by all of the
camptothecins was only significant and replicated at the highest
concentrations of each analogue. The overrepresented GO terms
and their associated genes under this QTL are listed in Table S2.
One plausible explanation for changes in patterns of observed
QTLs with differences in dose might be different mechanisms of
action predominating at different concentrations. It has been
reported that the anticancer activity of the camptothecins can
switch from a replication-dependent to transcription-dependent
process solely at higher concentrations in normal lymphoblasts and
other highly proliferative cell lines [9]. Also different DNA repair,
cell cycle checkpoint, and cell-death signaling pathways have been
implicated following DNA damage at different doses [27,28].
Without a doubt, there a number of complex mechanisms
associated with the cytotoxic activity of the camptothecins that
can occur simultaneously or selectively given certain intracellular
conditions [29]. Work is ongoing to identify the conditions that
dictate which pathways are preferred and why.
We have demonstrated that specific patterns of biological
response and QTLs could be established for a class of structurally
related drugs. When examining a drug class, slight changes in
structure also resulted in differences in patterns of QTLs
associated with cytotoxic response and drug action. To confirm
the ability of this model to stratify drugs based on mechanistic of
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action, future studies should be undertaken with drugs from
additional mechanistic classes. Biological and genomic profiling
should again reveal patterns which are chemical and class specific.
Moreover, as the ultimate goal of this research is correlate
biological response to genes involved in drug action, work is
needed to pinpoint the genes under these QTLs which are
influencing response. Thousands of genes are present in the seven
QTLs shared by all of the camptothecins. Recently, RNA
interference (RNAi) screens in model organisms and human cell
lines have successfully identified genes that modulate cell growth,
apoptosis, chemoresistance, and chemosensitivity [30–34]. Large
scale RNAi in the form of high throughput screens (HTS) using
small interfering RNAs (siRNA) can be used to systematically
screen all genes under the shared QTL. Known and novel genes
whose loss of function confers alterations in sensitivity to the
camptothecins can be identified. Taken together, these results lay
the groundwork for using the ex vivo familial genetic strategy in




The CEPH cell lines are a set of immortalized lymphoblastoid
cell lines collected from normal, healthy human volunteers which
can be purchased from Corriell Cell Repositories (Camden, NJ).
This collection is unique because the cell lines are established from
large multigenerational families and every individual within the
families has been genotyped, which enables investigators to
perform genetics & pharmacogenomic analyses [6,35,36]. For
the purposes of this study, all CEPH cell lines from the following
family identification numbers were used (http://ccr.coriell.org/
sections/collections/nigms/cephfamilies.aspx?PgId = 49): 35, 45,
1334, 1340, 1341, 1345, 1350, 1362, 1408, 1420, 1447, 1451,
1454, 1459, 1463. The cells were cultured in RPMI 1640
supplemented with 10% fetal bovine serum at 37uC in humidified
air containing 5% CO2 and passaged 2–3 times per week.
Exponentially growing lymphoblastoid cell lines at passages 3–7
were used for experimentation.
Drugs
The following camptothecin analogues (referred to as Camp-
tothecin Group A) were purchased from LKT Labs (St Paul, MN):
camptothecin (CPT), irinotecan (CPT11), 7-ethyl-10-hydroxy-
camptothecin (SN38), topotecan (TPT), 9-aminocamptothecin
(9AC) and 9-nitrocamptothecin (9NC). Dr. Daniel Comins (North
Carolina State University, Raleigh, NC) kindly provided the
members of Camptothecin Group B: 10-methoxycamptothecin
(mCPT), 10-hydroxycamptothecin (hCPT), and 7-chlorocamp-
tothecin (ClCPT). All camptothecins were prepared in 10 mM
working solutions of dimethyl sulfoxide (DMSO) (Sigma-Aldrich,
St Louis, MO). Since camptothecins have a labile lactone form
that exists in a pH dependent equilibrium with the inactive
carboxy form (present at basic pH), drugs were serially diluted in
citrate-phosphate buffer at pH 3. Final concentrations of DMSO
were 0.1% in all experiments.
Cytotoxicity Profiling
The cytotoxic effect of each panel of camptothecins was
determined by using the nontoxic colorimetric-based assay, alamar
blue [6]. Plates (384 well,Corning, Corning, NY) were preloaded
with vehicle (citrate-PBS, 0.1% DMSO), 10% DMSO, and
increasing concentrations of each drug (n = 9 concentrations per
drug). Each plate contained 6 replicates for each drug-dose
combination. Cells were then plated at a density of 4000 cells in
45 ul. Following 72 h incubation, 5 ul alamar blue was added.
Fluorescence was read (Ex 535 nm and Em 595 nm) using a
DTX880 plate reader (Beckman Coulter) at 96 h drug exposure.
Raw fluorescence values for each set of replicates of a drug-dose
combination were considered outliers if there was more than a ten-
fold increase or decrease in the fluorescence signal of a single
replicate. Growth inhibition relative to untreated controls was
determined according to the manufacturer’s protocol. The final
percent growth inhibition at each concentration was averaged
from six replicates of two independently plated experiments
(n = 12). Additionally, growth rate in vehicle was calculated as
previously described [12]. The IC50 (the dose needed to inhibit
growth by 50%), was calculated based on a sigmoidal dose-
response curve using the nls package in R (www.r-project.org)
[37].
Hierarchical Clustering
LogIC50s for each cell line-drug combination were z-score
transformed prior to clustering. The data was loaded into Cluster
3.0 (http://bonsai.ims.u-tokyo.ac.jp/,mdehoon/software/cluster/)
and clustered using uncentered correlation and complete linkage. To
stabilize clusters, a self organizing map (SOM) was calculated using
100,000 iterations for cell lines and 20,000 iterations for drugs.
Clusters were visualized using Java TreeView.
To compare the Top1 inhibitors to the Top2 inhibitors, the
concentration closest to yielding a population mean of 50% was
selected for each drug from the boxplot results provided in
Dataset S3. Hierarchical clustering analysis of cytotoxic response
to the Top1 and Top2 inhibitors was performed using the
percent growth inhibition for each cell line at the concentration
closest to yielding a population mean of 50% was selected for
each drug.
Heritability Analysis
Heritability estimates of the proportion of variation in cytotoxic
response due to inherited factors were calculated using variance
components analysis using MERLIN 1.1.2 (http://www.sph.
umich.edu/csg/abecasis/Merlin/index.html) [38]. The degree of
heritability associated with growth rate in vehicle was also
calculated, and the heritability calculation for each drug-dose
combination was adjusted using growth rate as a covariate in the
variance components analysis [38].
Genotype Data and Error Checking
Genotype data for each cell line were downloaded from V10 of
the CEPH database (ftp://ftp.cephb.fr/ceph_genotype_db/
ceph_db/Ver_10/mkr/) [39] using error checked markers.
Genetic map information was downloaded from the Marshfield
database (http://research.marshfieldclinic.org/genetics) [40]. Er-
ror checking for Mendelian incompatibility, misspecified relation-
ships and unlikely recombinations was performed, as previously
described [40]. A combined total of 8269 single nucleotide
polymorphisms (SNPs) and microsatellite markers were used for
linkage analysis.
Genome-Wide linkage Analysis
Drug-dose combinations were considered the phenotypes of
interest for linkage analysis (n = 54). For each phenotype, non-
parametric linkage analysis was performed using MERLIN which
constructs a likelihood ratio test for linkage based on inheritance
vectors. For quantitative traits, scores used to calculate the
likelihood ratio test are defined as follows:
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S(v)~S founder alleles Sallele(v)2
Sallele(v)~S all carriers of allele (yi{m)
where S(n) is the score for each inheritance vector, Sallele(n) is the
score for each founder allele, yi is the phenotype for each
individual, m is the mean phenotype for the population, and n is
the list of individuals who carry a specific founder allele such that
the score for each inheritance vector is the summation of the
squared score for each founder allele, and the score for each found
allele is the sum of square deviation from all individuals that carry
that allele. For each phenotype of interest, QTL maps were
generated by displaying the logarithm of odds (LOD) scores from
the likelihood ratio tests across each chromosome. The LOD score
is a statistical estimate of linkage; it is the ratio of the likelihood
that a chromosomal region is linked to the phenotype of interest
over the likelihood that it is not. A LOD score of three indicates
1000 to 1 odds that the region is linked.
Peak Identification
Guidelines for interpreting LOD scores have suggested viewing
LOD scores of 2.2 as suggestive and 3.6 as significant [41]. However,
since such a categorization is inexact, the data in this study was used
to dictate at which threshold results would no longer be considered
due to chance and most likely occur as a result of linkage. For each
drug-dose phenotype, gene-dropping permutations were conducted
using Merlin to get a distribution of LOD scores which would occur
under the null hypothesis of no linkage to the observed drug-dose
phenotypes [38]. Marker data were simulated under the null
hypothesis of no linkage or association to the observed phenotypes
while retaining the same pedigree structures, maps, marker allele
frequencies, and missing data patterns. Ten thousand replicates were
simulated for each of the 54 phenotypes, resulting in a total of 54,000
simulated datasets. Linkage analysis was conducted as described
above for each replicate set. Based on these simulations, permutation
distributions were generated across the chromosomes for each drug-
dose phenotype and then used to determine genome-wide LOD score
cut-offs corresponding to p-values less than or equal to .05 for each
phenotype. Additionally, cutoffs for suggestive linkage were deter-
mined for each drug-dose combination for an alpha of 0.05 for each
chromosome. A complete list of LOD score significant and suggestive
cut-offs can be found in Dataset S1. QTLs observed for a drug-dose
phenotype were considered significant if the highest LOD score in
that region surpassed the significance LOD score threshold for that
drug-dose phenotype. QTLs observed for a drug-dose phenotype
were considered suggestive if the highest LOD score in that region
surpassed the suggestive LOD score threshold for that drug-dose
phenotype on that chromosome. Dataset S2 contains a list of QTLs
identified as significant for drug-dose phenotypes as well as a those
QTLs which are replicated within the panel of camptothecins.
Supporting Information
Figure S1 Dose–response curve for camptothecin ana-
logues. Data points represent the overall population mean
(n = 126) for growth inhbition relative to untreated controls at each
dose. Vertical bars represent the standard deviation for cell
viability across the population. Numbers are the growth-rate
adjusted heritability estimates for each concentration. IC50
represents overall population IC50.
(PDF)
Figure S2 Hierarchal clustering of log transformed
IC50s for camptothecins in CEPH cell lines. Log IC50s
were z-score transformed. Clustering based on drugs holding
family structure intact. Yellow color indicates positive Z-scores
(resistance), blue color indicates negative Z-scores (sensitive), black
color indicates Z-score = 0 (median resistance value). The brighter
the color the greater the value from 0, with max brightness set at
2.5. Black and white bar indicates family structure (n = 14
pedigrees).
(PDF)
Figure S3 Differences in biological activity between
Top1 and Top2 inhibitors in CEPH cell lines. Hierarchal
clustering of z-score transformed mean cell viabilities at the dose
which yields population mean IC50. Clustered on both drugs and
cell lines. Yellow color indicates positive Z-scores (resistance), blue
color indicates negative Z-scores (sensitive), black color indicates
Z-score = 0 (median resistance value). The brighter the color the
greater the value from 0, with max brightness set at 2.5.
(PDF)
Table S1 Similarity matrix of overall QTL patterns for
each camptothecin. To compare the overall QTL patterns
between each of the camptothecin analogues a similarity matrix
was constructed using a binary assessment of peaks present at
either the significant or suggestive level for each camptothecin R
squared correlations (r2) are bound by 0 and 1 and the greater the
value the more related the overall QTL patterns are to each other.
(DOCX)
Table S2 Genes under QTLs shared by camptothecins.
The functional annotation clustering tool from the web-accessible
program Database for Annotation, Visualization, and Integrated
Discovery (DAVID) was used to identify over-represented gene
ontology terms (GO) and KEGG pathways for genes under each
of the shared QTLs on chromosomes 1, 5, 11, 16 and 20. Genes of
interest are listed by chromosomal location and then gene
ontology term. The bolded gene names in Table S1 have
previously been associated with camptothecin activity in yeast
and/or mammalian cell lines.
(DOCX)
Table S3 Genes under QTLs of interest for the camp-
tothecins. DAVID was used to identify over-represented gene
ontology terms (GO) and KEGG pathways for genes located
under the QTL on chromosome 1 for which a linkage with CPT
bearing a nitrogen atom in position 9 is reported. Genes of interest
are also listed for the QTL observed on chromosome 13
correlating uniquely with topotecan treatment and on chromo-
some 5 which is in linkage only with CPT11, 9AC and 9NC.
(DOCX)
Dataset S1 LOD score thresholds. Gene dropping permu-
tations were used to identify LOD score thresholds for significant
and suggestive linkage. LOD score cut-offs corresponding to a
genome-wide p-values less than or equal to .05 for each drug at
each dose were found, and used to define significant LOD score
peaks. LOD score cut-offs corresponding to a genome-wide p-
values less than or equal to .05 for each drug at each dose were
found, and used to define significant LOD score peaks. LOD score
cutoffs for suggestive peaks were defined as the minimum LOD
score to achieve a p-value of 0.05 at each chromosome for each
drug-dose phenotype. Significant and suggestive peak thresholds
for each drug-dose combination on each chromosome as
generated by permutation analysis are listed.
(XLS)
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Dataset S2 Details of significant, suggestive, and repli-
cating peaks for camptothecins. Tab 1 lists all significant
QTLs by chromosome. The chromosome, the beginning and end
of all peaks in centiMorgan (cM) units, and the peak LOD score in
the region are listed. Additionally, drug-dose combinations which
replicate the significant QTLs (LOD score.suggestive peak
threshold at that location) are listed along with their maximum
LOD score in that region (tab 2). As before, the chromosome, the
beginning and end of all peaks in centiMorgan (cM) units, and the
peak LOD score in the region are listed for each drug-dose
combination. Drug-dose combinations with a significant peak are
indicated in bold.
(XLS)
Dataset S3 Boxplots illustrating variance in cell viability
across the entire CEPH population (n = 125) for each drug.
Line represents mean phenotypic response, whiskers box represents
upper and lower quartiles, and whiskers are 1.5*IQR. Outliers
(circles) are individuals whose mean viability is greater than 1.5*IQR.
(PDF)
Dataset S4 Boxplots illustrating intra- and inter-family
variance in cell viability of each drug and dose across
CEPH families. Line represents mean phenotypic response,
whiskers box represents upper and lower quartiles, and whiskers
are 1.5*IQR. Outliers (circles) are individuals whose mean
viability is greater than 1.5*IQR.
(PDF)
Dataset S5 Genomewide QTL plots for each drug and
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